Purpose of reviewFree-living amebae (FLA) including Naegleria fowleri, Balamuthia mandrillaris, and Acanthamoeba species can cause rare, yet severe infections that are nearly always fatal. This review describes recent developments in epidemiology, diagnosis, and treatment of amebic meningoencephalitis.
Recent findingsDespite similarities among the three pathogenic FLA, there are notable variations in disease presentations, routes of transmission, populations at risk, and outcomes for each. Recently, molecular diagnostic tools have been used to diagnose a greater number of FLA infections. Treatment regimens for FLA have historically relied on survivor reports; more data is needed about novel treatments, including nitroxoline.
SummaryResearch to identify new drugs and guide treatment regimens for amebic meningoencephalitis is lacking. However, improved diagnostic capabilities may lead to earlier diagnoses, allowing earlier treatment initiation and improved outcomes. Public health practitioners should continue to prioritize increasing awareness and providing education to clinicians, laboratorians, and the public about amebic infections.
Keywords amebic meningoencephalitis, encephalitis, free-living ameba
&&]. PAM is a rapidly progressive disease acquired when water containing the ameba enters the nose allowing the amebae to travel to the brain, causing diffuse inflammation, cerebral edema, and ultimately, herniation. Initial signs and symptoms can include fever, headache, vomiting, and meningismus, and progresses to death in a median of 5 days. It most commonly occurs in healthy adolescent male individuals in warm, summer months. GAE, in contrast, is more common among adults, has a more insidious onset and course, and likely results from hematogenous spread of amebae to the brain after exposure through inhalation or skin exposure. GAE can present with fever, headache, altered mental status, or seizures, and progresses over weeks to months. The recommended treatment